Key Highlights
- Fusion Antibodies plc (LSE:FAB) shares fell more than 41% to 5.75p on 15 October 2026 after a weak first-half trading update.
- Revenue for the six months to 30 September 2026 fell to about £457,000 from £838,000 a year earlier.
- Gross margin dropped to 10% from 30%, and cash stood at £135,000 at the period end.
- The board is reviewing working capital, has frozen recruitment and expects more than £100,000 of grant funding shortly.
- Scientific progress continued, including encouraging DR5 cancer antibody data and interest in OptiMAL from the US National Cancer Institute.
Why Fusion Antibodies Is in Focus on 16 October 2026
Fusion Antibodies plc (LSE:FAB), the Belfast-based antibody discovery and engineering company quoted on the London Stock Exchange's AIM market and part of the FTSE AIM All-Share universe, is in sharp focus on 16 October 2026 following a dramatic sell-off a day earlier. On 15 October the shares fell more than 41% to 5.75p in morning trading after the company warned that difficult market conditions had hit its first-half performance.
The update, delivered alongside its annual general meeting, revealed a steep fall in revenue, a collapse in gross margin and a very low cash balance. With the board now reviewing the company's working capital position, investors are focused on how Fusion will fund itself through the second half.
Latest Developments: A Tough First Half
Fusion said revenue for the six months to 30 September 2026 fell to roughly £457,000 from £838,000 in the same period last year, a decline of around 45%. Gross margin fell to 10% from 30%, reflecting weaker volumes against a largely fixed cost base. Cash at the period end was £135,000, and the company expects to receive more than £100,000 in grant funding shortly.
Management has responded with cost cuts, including a freeze on recruitment, while the board reviews working capital needs. The company has not announced any fundraising, but the scale of the cash position has led market participants to speculate that new equity may be required. For the second half, Fusion said its priorities are converting its commercial pipeline into revenue and broadening adoption of its technology. No numerical guidance was given.
Science Still Moving Forward
Despite the financial pressure, the company highlighted progress in its research programmes. In its DR5 cancer antibody programme, an initial mouse study showed that two of four antibody formats significantly slowed tumour growth, and a second study is being prepared. Its OptiMAL discovery platform has attracted interest from the US National Cancer Institute, and Fusion is negotiating a further agreement. The company has also secured new patents in Japan, Canada and other territories.
Business and Financial Background
Fusion Antibodies operates as a contract research organisation, offering antibody discovery, engineering and supply services to pharmaceutical and biotech clients, while developing its own platforms such as OptiMAL. Chief Executive Adrian Kinkaid leads the business, and Simon Douglas is chair.
The latest update marks a sharp reversal from the year to 31 March 2026. In that period, revenue rose 7% to £2.1 million from £1.97 million, with second-half revenue up 21% to £1.02 million. Gross margin improved to 58.3% from 22%, and the operating loss narrowed to £1.13 million from a restated £1.63 million despite higher spending on OptiMAL. Cash stood at £1.04 million at the year end, helped by a January 2026 fundraise of about £1.4 million before expenses at 13p per share.
However, the annual accounts already flagged a material uncertainty over going concern and said additional funding was expected to be needed. Chair Simon Douglas warned that market conditions remained difficult and were weighing on early performance in the 2027 financial year.
Sector and Market Context
Early-stage drug discovery spending has been subdued, with biotech funding constraints leading many clients to delay or cut outsourced research. Smaller contract research organisations have been particularly exposed, as project timing can swing revenue sharply from one half to the next. Fusion is trying to win work from larger organisations, but commercial agreements for new platforms such as OptiMAL tend to take time. Across AIM healthcare, investors have become increasingly cautious towards companies with short cash runways.
What Investors Are Watching Next
The outcome of the working capital review is the most important near-term issue for LSE:FAB. Investors will be watching for any funding announcement, receipt of the expected grant funding, and progress on converting the commercial pipeline into orders. A signed agreement with the US National Cancer Institute, results from the second DR5 study, and any commercial OptiMAL deals would be key positive catalysts. Interim results for the six months to 30 September 2026 are also due in the coming months.
Key Risks
Fusion's cash balance of £135,000 is very low relative to its cost base, and the company has already flagged a material uncertainty over going concern. A fundraise at a discount could cause significant dilution. Revenue is volatile and dependent on client spending in a weak market. Scientific progress may not translate into near-term revenue, and the share price has shown extreme volatility.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...